Drugs / VEGFR1-1084
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00639925 | Mar 2007 → Mar 2013 | malignant pancreatic neoplasm | Fukushima Medical University | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00655785 | Sep 2007 → Mar 2013 | malignant pancreatic neoplasm | Fukushima Medical University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VEGFR1-1084 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00639925 ↗ |
| Modality | Peptide | “restricted epitope peptide VEGFR1 and VEGFR2 emulsified with Montanide ISA 51” NCT00655785 ↗ |
| Route | Subcutaneous | “administered by subcutaneous injection” NCT00639925 ↗ |